Strong Fundamentals Outweigh Limited Nanjing Impact
Strategic Expansion and Market Performance
Catastrophic Quarterly Performance
Institutional Interest Returns Despite Headwinds
Capital Restructuring and Market Response
Viking Therapeutics US92686J1060